Smith & Nephew 

€14.21
547
+€0.01+0.07% Wednesday 13:36

統計

當日最高
14.21
當日最低
14.21
52週高點
-
52週低點
-
成交量
300
平均成交量
-
市值
0
本益比
-
股息殖利率
2.38%
股息
0.34

即將到來

股息

2.38%股息殖利率
Nov 25
€0.13
May 25
€0.21
Nov 24
€0.13
May 24
€0.21
Nov 23
€0.14
10年成長
2.04%
5年成長
1.24%
3年成長
-1.13%
1年成長
不適用

財報

2Mar預期
Q2 2025
下一步
0.34
0.39
0.45
0.5
預期EPS
0.49727654921000003
實際EPS
不適用

財務

7.08%利潤率
有盈利
2019
2020
2021
2022
2023
2024
5.52B營收
391M淨利

其他人也在關注

此清單是根據在 Stock Events 上追蹤 NPW1.XETRA 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Show more...
執行長
Ms. Anne-Francoise Nesmes
員工
18000
國家
UK
ISIN
GB0009223206
WKN
000502816

上市

0 Comments

分享你的想法

FAQ

Smith & Nephew 今天的股價是多少?
NPW1.XETRA 目前價格為 €14.21 EUR,過去 24 小時上漲了 +0.07%。在圖表上更密切關注 Smith & Nephew 股價表現。
Smith & Nephew 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Smith & Nephew 的股票以代號 NPW1.XETRA 進行交易。
Smith & Nephew 下一次財報日期是什麼時候?
Smith & Nephew 將於 March 02, 2026 公布下一次財報。
Smith & Nephew 上一季度的財報如何?
NPW1.XETRA 上一季度的財報為每股 0.37 EUR,預估為 0.34 EUR,帶來 +8.6% 的驚喜。下一季度的預估財報為每股 不適用 EUR。
Smith & Nephew 去年的營收是多少?
Smith & Nephew 去年的營收為 5.52BEUR。
Smith & Nephew 去年的淨利是多少?
NPW1.XETRA 去年的淨收益為 391MEUR。
Smith & Nephew 會發放股息嗎?
是的,NPW1.XETRA 的股息每 半年一次 發放一次。每股最新股息為 0.13 EUR。截至今日,股息殖利率(FWD)% 為 2.38%。
Smith & Nephew 有多少名員工?
截至 February 03, 2026,公司共有 18,000 名員工。
Smith & Nephew 位於哪個產業?
Smith & Nephew從事於Healthcare產業。
Smith & Nephew 何時完成拆股?
Smith & Nephew 最近沒有進行任何拆股。
Smith & Nephew 的總部在哪裡?
Smith & Nephew 的總部位於 UK 的 Watford。